

### *MolMed Shareholders' Meeting:*

- *approves 2016 Financial Statements;*
- *expresses favourable opinion on the Report on remuneration;*
- *approves updated General Meeting regulations.*

Milano, April 10, 2017 – The Shareholders' Meeting of MolMed S.p.A. (MLM.MI), met today under the chairmanship of Professor Claudio Bordignon and resolved upon the items of the agenda as follows:

#### **Approval of the Statutory Financial Statements for year 2016. Resolutions related and consequent thereto**

In 2016, thanks to a steady revenue growth (+36.2% respect to 2015) and to a reduction in operating costs (-2.4% respect to 2015), Statutory Financial Statements results improved by more than 33.0% respect to 2015. The positive net financial position at December 31, 2016, is equal to Euro 19.7 million and consists of cash and current financial assets, in absence of financial indebtedness.

The Shareholders' Meeting, having duly noted the Statutory Auditors' and Independent Auditors' Reports, approved the Statutory Financial Statements for the fiscal year ended December 31, 2016, as submitted, resolving to carry forward the overall loss of Euro 13.876 thousand.

#### **Report on remuneration – Section I: resolution pursuant to art. 123-ter of Legislative Decree No. 58/1998**

The Shareholders' Meeting expressed a favourable opinion on the Section I of the Report on the remuneration policy. Section I of the above-mentioned Report details principles and purposes of the Company remuneration Policy for Board directors, general manager and strategic directors for FY 2017, as well as the related procedures implemented in order to adopt and implement the policy.

#### **General Meeting Regulations' update. Resolutions related and consequent thereto**

The Shareholders' Meeting approved an update of the Meeting Regulations, adopted on October 29, 2007. The Meeting Regulations amendments aim to reflect the provisions of the new By-law as approved on November 7, 2016, as well as the existing applicable provisions of law, while preserving the matter of its contents and Shareholders' rights.

#### **FROM GENES TO THERAPY**

---

#### **MOLMED S.p.A.**

Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325  
info@molmed.com - [www.molmed.com](http://www.molmed.com)

Share capital €20,312,682.30 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159

\*\*\*

In accordance with the provisions of art. 125-quater, paragraph 2, of the TUF and art. 77, paragraph 3, of the Issuers' Regulations, a summary report containing the number of voting shares represented at the meeting and the actions for which the vote was cast, the percentage of capital that these shares represent, as well as the number of votes for and against the resolutions and the number of abstentions, will be made available to the public within five days from the date of the Shareholders' meeting on the Company's website.

\*\*\*

The minutes of the Shareholders' Meeting will be made available to the public according to the terms provided by the laws and regulations in force.

\*\*\*

The official manager responsible for preparing the Company's financial reports, Andrea Quaglino, herewith attests, pursuant to Article 154-bis, paragraph 2 of the Italian Consolidated Law on Finance (Legislative Decree 58/1998, as amended), that the accounting disclosure contained in this press release matches documentary evidence, corporate books, and accounting records.

---

This press release is written in compliance with public disclosure obligations established by Consob's (Italian securities & exchange commission) Issuers Regulation.

### *About MolMed*

MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes anti-tumour therapeutics in clinical and preclinical development: Zalmoxis® (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression prophylaxis, currently in Phase III in high-risk acute leukaemia and granted a Conditional Marketing Authorisation by the European Commission; NGR-hTNF is a novel therapeutic agent for solid tumours which displays antitumor activity through its specific binding to blood vessels feeding the cancer and to the concentration of immune system cells into the tumour mass, currently investigated in a broad clinical programme, involving more than 1000 treated patients; CAR-CD44v6 is an immune gene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP manufacturing of viral vectors and patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biotechnology Department (DIBIT) in Milan, Italy, and has an operating unit at OpenZone in Bresso (Milan, Italy). MolMed is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana (ticker Reuters: MLMD.MI).

### *For further information:*

#### **Laura Villa**

#### **Investor Relations & Communication Director**

MolMed S.p.A.

phone: +39 02 21277.205

fax: +39 02 21277.325

e-mail: [investor.relations@molmed.com](mailto:investor.relations@molmed.com)

#### **Press agent**

#### **Federico Ferrari**

SEC Relazioni Pubbliche e Istituzionali s.r.l.

phone: +39 02 6249991 – mobile +39 347 6456873

e-mail: [ferrari@segrp.it](mailto:ferrari@segrp.it)

#### **DISCLAIMER**

*This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A..*